Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-03T02:41:09.709Z Has data issue: false hasContentIssue false

Chemotherapy in cerebrospinal meningitis in the Sudan

Published online by Cambridge University Press:  15 May 2009

R. M. Buchanan
Affiliation:
Senior Medical Inspector, Sudan Medical Service
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

1. Meningococcal cerebrospinal meningitis in the Sudan does not materially differ in its progress and end result from the disease as found in Europe.

2. There is no racial peculiarity in response to infection or to chemotherapy.

3. There is no sex or age peculiarity in incidence. Both sexes and all ages respond to chemotherapy.

4. Sulphapyridine is superior to sulphanilamide in the shortening of invalidism and in the prevention of complications.

5. Oral administration of sulphapyridine is in the majority of cases as effective as intramuscular.

6. Dosage is related to the clinical stage of the disease, and to its duration before treatment. An initial dose of 2·5 g. sulphapyridine for adults, and 1·0—1·5 g. for children is prescribed for the serious case, with subsequent gradation of treatment to provide a maintenance dose.

7. Treatment, if it is going to give a good result, will produce a response within 24 hr. It need not be prolonged beyond 7 days. The third, fourth and seventh days of treatment are critical.

Type
Research Article
Copyright
Copyright © Cambridge University Press 1940

References

REFERENCES

Banks, H. S. (1938). Serum and sulphanilamide in acute meningococcal meningitis. Lancet, 2, 713.CrossRefGoogle Scholar
Banks, H. S. (1939). Chemotherapy of meningococcal meningitis. Lancet, 2, 921–6.CrossRefGoogle Scholar
Banks, H. S. (1940). Cerebrospinal fever. Lancet, 1, 42–4.Google Scholar
Bryant, J. & Fairman, H. D. (1939). Chemotherapy of cerebrospinal fever in the field. Lancet, 1, 923–6.CrossRefGoogle Scholar
Cook, A. B. (1939). Brit. med. J. p. 1154 (correspondence).CrossRefGoogle Scholar
Corkhill, N. L. (1936). Vitamin A prophylaxis in epidemic meningococcal meningitis. J. trop. Med. (Hyg.), 39, l4.Google Scholar
Corkhill, N. L. (1939). Climate as a factor in epidemic meningitis in Kordofan. Lancet, 1, 1203–5.CrossRefGoogle Scholar
Council of Pharmacy, Amer. Med. Ass. (1939). J. Amer. med. Ass. 112, 1831.Google Scholar
Crawford, T. & Fleming, G. B. (1938). Treatment of meningococcal meningitis with sulphanilamide. Lancet, 1, 987–91.CrossRefGoogle Scholar
Hobson, F. G. & MacQuaide, D. H. G. (1938). Treatment of meningococcal meningitis with 2-sulphanilyl-amidopyridine (M. & B. 693). Lancet, 2, 1213–17.CrossRefGoogle Scholar
Jewesbury, E. C. O. (1938). The use of sulphanilamide in the treatment of meningococcal meningitis. Lancet, 1, 1262–4.CrossRefGoogle Scholar
Long, P. H. (1939). Lancet, 1, 60 (correspondence).CrossRefGoogle Scholar
Marshall, E. K., Cutting, W. C. & Emerson, K. (1937). Para-aminobenzenesulfonamide; absorption and excretion; method of determination in urine and blood. J. Amer. med. Ass. 108, 953–7.CrossRefGoogle Scholar
Proom, H. (1938). Estimation of sulphanilamide in blood and other body fluids. Lancet, 1, 260–1.CrossRefGoogle Scholar
Riding, D. & Corkhill, N. L. (1932). Prophylactic vaccination in epidemic meningococcal meningitis. J. Hyg., Camb., 32, 258–67.CrossRefGoogle ScholarPubMed
Schwentker, F. F., Gelman, S. & Long, P. H. (1937). Treatment of meningococcal meningitis with sulfanilamide; preliminary report. J. Amer. med. Ass. 108, 1407–8.CrossRefGoogle Scholar
Somers, R. B. U. (1939). M. & B. 693 in cerebrospinal fever. Lancet, 1, 921–2.CrossRefGoogle Scholar
Tidy, Letheby (1937). Brit. Encycl. med. Pract. 3. Butterworth and Co.Google Scholar
Walsh, G. (1938). Fatality rates in cerebrospinal meningitis. J. Amer. med. Ass. 110, 1894–6.CrossRefGoogle Scholar
Whitby, L. E. H. (1938). Chemotherapy of pneumococcal and other infections with 2-(P-aminobenzenesulphonamido)pyridine. Lancet, 1, 1210–12.CrossRefGoogle Scholar